Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine | Zendy

Edson Duarte Moreira | Zendy; Nicholas Kitchin | Zendy; Xia Xu | Zendy; Samuel S. Dychter | Zendy; Stephen Lockhart | Zendy; Alejandra Gurtman | Zendy; John L. Perez | Zendy; Cristiano A. F. Zerbini | Zendy; Michael Dever | Zendy; Timothy W Jennings | Zendy; Donald Brandon | Zendy; Kevin D Can | Zendy; Michael Koren | Zendy; Douglas Denham | Zendy; Mezgebe Berhe | Zendy; David Fitz-Patrick | Zendy; Laura L Hammitt | Zendy; Nicola P. Klein | Zendy; Haylene Nell | Zendy; Georgina Keep | Zendy; Xingbin Wang | Zendy; Kenneth Koury | Zendy; Kena A. Swanson | Zendy; David Cooper | Zendy; Claire Lu | Zendy; Özlem Türeci | Zendy; Eleni Lagkadinou | Zendy; Dina B Tresnan | Zendy; Philip R. Dormitzer | Zendy; Uǧur Şahin | Zendy; William C. Gruber | Zendy; Kathrin U. Jansen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Author(s) -

Edson Duarte Moreira,

Nicholas Kitchin,

Xia Xu,

Samuel S. Dychter,

Stephen Lockhart,

Alejandra Gurtman,

John L. Perez,

Cristiano A. F. Zerbini,

Michael Dever,

Timothy W Jennings,

Donald Brandon,

Kevin D Can,

Michael Koren,

Douglas Denham,

Mezgebe Berhe,

David Fitz-Patrick,

Laura L Hammitt,

Nicola P. Klein,

Haylene Nell,

Georgina Keep,

Xingbin Wang,

Kenneth Koury,

Kena A. Swanson,

David Cooper,

Claire Lu,

Özlem Türeci,

Eleni Lagkadinou,

Dina B Tresnan,

Philip R. Dormitzer,

Uǧur Şahin,

William C. Gruber,

Kathrin U. Jansen

Publication year - 2022

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2200674

Subject(s) - reactogenicity , medicine , placebo , booster dose , randomized controlled trial , covid-19 , clinical trial , pediatrics , immunization , immunology , infectious disease (medical specialty) , disease , alternative medicine , pathology , antigen

Active immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic. In light of reports of waning protection occurring 6 months after the primary two-dose vaccine series, data are needed on the safety and efficacy of offering a third (booster) dose in persons 16 years of age or older.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research